ArticleFrontiers in endocrinology2022
A nomogram model based on clinical markers for predicting malignancy of ovarian tumors.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Diagnostic value of the Risk of Ovarian Malignancy Algorithm (ROMA) index in the detection of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- Development and validation of a nomogram for predicting postoperative venous thromboembolism risk in patients with hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- Prognostic significance of chemotherapy response score in predicting outcomes for high-grade serous ovarian carcinoma patients undergoing neoadjuvant chemotherapy.Translational cancer research · 2025Article
- Decision tree model for predicting ovarian tumor malignancy based on clinical markers and preoperative circulating blood cells.BMC medical informatics and decision making · 2025Article
- A nomogram to predict the risk of venous thromboembolism in patients with colon cancer in China.Cancer medicine · 2024Article
- Survival time prediction in patients with high-grade serous ovarian cancer based onBMC cancer · 2024Article
- A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure.Frontiers in medicine · 2024Article
- A nomogram for predicting breast cancer based on hematologic and ultrasound parameters.American journal of translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to build a nomogram based on clinical markers for predicting the malignancy of ovarian tumors (OTs). Method: A total of 1,268 patients diagnosed with OTs that were surgically removed between October 2017 and May 2019 were enrolled. Clinical markers such as post-menopausal status, body mass index (BMI), serum human epididymis protein 4 (HE4) value, cancer antigen 125 (CA125) value, Risk of Ovarian Malignancy Algorithm (ROMA) index, course of disease, patient-generated subjective global assessment (PG-SGA) score, ascites, and locations and features of masses were recorded and analyzed ( Result: The significant variables included post-menopausal status, BMI, HE4 value, CA125 value, ROMA index, course of disease, PG-SGA score, ascites, and features and locations of masses ( Conclusion: We successfully tailored a nomogram model based on selected clinical markers which showed superior prognostic predictive accuracy compared with the use of the CA125, HE4, or ROMA index (that combines both HE and CA125 values) for predicting the malignancy of OT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.